Crescent Biopharma Inc. (NASDAQ: CBIO) announced it will present a trial in progress poster for its ASCEND study of CR-001 at the American Society of Clinical Oncology Annual Meeting from May 29 to June 2 in Chicago.

CR-001 is a PD-1 x VEGF bispecific antibody being evaluated in the ASCEND Phase 1/2 global clinical trial for multiple solid tumor types, including non-small cell lung cancer and gastrointestinal and gynecological cancers. The study is enrolling up to 290 patients across dose-escalation, backfill and dose-optimization cohorts in the United States, Europe and Asia Pacific.

The trial's primary objectives focus on evaluating safety and tolerability of CR-001. Secondary objectives include assessing pharmacokinetic and pharmacodynamic profiles, identifying the recommended Phase 2 dose, and evaluating preliminary antitumor activity measures including overall response rate, duration of response, progression-free survival and overall survival.

"CR-001 is designed to serve as an immuno-oncology backbone and best-in-class PD-1 x VEGF bispecific antibody for people living with cancer," said Ellie Im, chief medical officer of Crescent.

Crescent anticipates reporting proof-of-concept clinical data from the ASCEND trial in the first quarter of 2027, including initial safety, pharmacokinetics, pharmacodynamics and preliminary antitumor activity data. The company expects initial combination data with standard of care chemotherapy in mid-2027, and initial data from a Phase 1/2 trial in China combining CR-001 with a Kelun-Biotech antibody-drug conjugate also in mid-2027.

The poster presentation will occur Saturday, May 30 from 1:30 p.m. to 4:30 p.m. CDT in Hall A.